In compliance with ASX Continuous Disclosure Rules, Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to report it has now executed a Settlement and Release Agreement with Reproductive Genetics Institute, Inc. of Chicago, Illinois, USA.

In late August 2012, GTG reported it had filed suit against Reproductive Genetics Institute, Inc. in the United States District Court for the Northern District of Illinois, Eastern Division under its Assertion program in USA. Now that a final settlement has been reached with Reproductive Genetics Institute, the US attorneys acting for GTG will now dismiss this law suit. The precise commercial terms of the Agreement are covered by formal confidentiality provisions and cannot be disclosed.

AboutGenetic Technologies Limited

Genetic Technologies was an early pioneerin recognizing important new applicationsfor “non?coding” DNA (Deoxyribonucleic Acid). The Company hassince been granted patentsin 24 countries around the world,securing intellectual property rightsfor particular uses of non?codingDNA in genetic analysis and genemapping across all genesin allspecies. Its businessstrategy isthe global commercialization ofits patentsthrough an active out?licensing program and the global expansion of its oncology and cancer management diagnostics portfolio.

Genetic Technologiesis an ASX and NASDAQlisted company with operationsin the USA and Australia. For more information, please visit www.gtglabs.com.